Equities research analysts expect pSivida Corp. (NASDAQ:PSDV) to report ($0.15) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Three analysts have provided estimates for pSivida’s earnings. The highest EPS estimate is ($0.14) and the lowest is ($0.17). The firm is scheduled to issue its next earnings results on Tuesday, February 6th.

On average, analysts expect that pSivida will report full year earnings of ($0.59) per share for the current year, with EPS estimates ranging from ($0.67) to ($0.53). For the next financial year, analysts anticipate that the business will report earnings of ($0.09) per share, with EPS estimates ranging from ($0.49) to $0.66. Zacks Investment Research’s EPS averages are a mean average based on a survey of research analysts that that provide coverage for pSivida.

pSivida (NASDAQ:PSDV) last posted its quarterly earnings data on Tuesday, November 7th. The company reported ($0.15) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.15). The business had revenue of $0.39 million during the quarter, compared to the consensus estimate of $0.74 million. pSivida had a negative return on equity of 139.56% and a negative net margin of 226.31%.

Several research firms have recently weighed in on PSDV. HC Wainwright reissued a “buy” rating and issued a $5.00 price objective on shares of pSivida in a report on Wednesday, September 27th. B. Riley set a $5.00 price objective on pSivida and gave the company a “buy” rating in a report on Friday, December 15th. ValuEngine downgraded pSivida from a “sell” rating to a “strong sell” rating in a report on Friday, December 1st. Laidlaw began coverage on pSivida in a report on Wednesday, November 8th. They issued a “buy” rating and a $5.00 price objective for the company. Finally, Northland Securities reissued a “buy” rating and issued a $10.00 price objective on shares of pSivida in a report on Monday, December 11th. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the company. The company has a consensus rating of “Buy” and a consensus price target of $7.57.

A hedge fund recently bought a new stake in pSivida stock. OxFORD Asset Management LLP purchased a new position in shares of pSivida Corp. (NASDAQ:PSDV) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm purchased 69,004 shares of the company’s stock, valued at approximately $118,000. OxFORD Asset Management LLP owned 0.18% of pSivida at the end of the most recent reporting period. Hedge funds and other institutional investors own 9.70% of the company’s stock.

pSivida (PSDV) traded up $0.03 during mid-day trading on Tuesday, hitting $1.08. The stock had a trading volume of 248,864 shares, compared to its average volume of 524,075. The firm has a market capitalization of $48.88, a P/E ratio of -2.35 and a beta of 1.34. pSivida has a 1-year low of $1.02 and a 1-year high of $2.45.

ILLEGAL ACTIVITY WARNING: “Zacks: Analysts Expect pSivida Corp. (PSDV) Will Announce Earnings of -$0.15 Per Share” was first published by Watch List News and is the property of of Watch List News. If you are accessing this story on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this story can be read at https://www.watchlistnews.com/zacks-analysts-expect-psivida-corp-psdv-will-announce-earnings-of-0-15-per-share/1790014.html.

About pSivida

pSivida Corp. develops drug delivery products primarily for the treatment of chronic eye diseases. The Company operates through the biotechnology sector segment. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert.

Get a free copy of the Zacks research report on pSivida (PSDV)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for pSivida (NASDAQ:PSDV)

Receive News & Ratings for pSivida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for pSivida and related companies with MarketBeat.com's FREE daily email newsletter.